Treatment(s) already received-Biological therapy - Page 4 of 4 Posts on Medivizor
Navigation Menu

Treatment(s) already received-Biological therapy Posts on Medivizor

Can we predict high-intensity focused ultrasound success before treatment?

Can we predict high-intensity focused ultrasound success before treatment?

Posted by on Nov 14, 2014 in Prostate cancer | 0 comments

In a nutshell This paper studied factors that might influence prostate-specific antigen (PSA) nadir levels following high-intensity ultrasound treatment in patients whose cancer has not spread beyond the prostate. Some background High-intensity focused ultrasound (HIFU) is a primary treatment in prostate cancer that targets and removes damaged or...

Read More

Skin-sparing mastectomy; an acceptable treatment?

Skin-sparing mastectomy; an acceptable treatment?

Posted by on Oct 25, 2014 in Breast cancer | 0 comments

In a nutshell This paper studied the outcomes of a skin-sparing mastectomy procedure. Some background More and more people are undergoing skin-sparing mastectomies. This is a treatment for breast cancer where breast tissue is removed, but the overlying skin is preserved as much as possible. It also allows for immediate breast...

Read More

Local therapies with continued EGFR tyrosine kinase inhibitors (erlotinib or gefitinib) for resistant non-small cell lung cancer

Posted by on Aug 4, 2013 in Lung cancer | 0 comments

In a nutshell This study examined the benefits of local therapies for patients with EGFR mutant non-small cell lung cancer (NSCLC) that has progressed despite tyrosine kinase inhibitor (TKI) treatment. Some background Non-small-cell lung cancer (NSCLC) cells may contain different genetic mutations that cause these cells to divide and spread...

Read More

Recurrence of breast cancer in the central nervous system (CNS) associated with trastuzumab treatment

Posted by on Jul 20, 2013 in Breast cancer | 0 comments

In a nutshell This large analysis determined the risk of CNS metastases as the first site of recurrence in patients with HER2-positive breast cancer who received trastuzumab (herceptin). Some background Breast cancer recurrence (return of the cancer) may occur near the site of the original cancer, or at other distant locations. The central nervous...

Read More

Can removal of the axillary lymph nodes be avoided if there is minimal involvement of the sentinel lymph nodes in breast cancer?

Can removal of the axillary lymph nodes be avoided if there is minimal involvement of the sentinel lymph nodes in breast cancer?

Posted by on Jun 29, 2013 in Breast cancer | 0 comments

In a nutshell This study tested the effect of complete axillary lymph node removal, on survival without recurrence of the cancer (called disease free survival or DFS) in patients with breast cancer.  Some background Lymph nodes are small organs which are part of the immune system. They filter fluid called lymph. Lymph can be thought of as the...

Read More

Phase II clinical trial evaluating the combination of cetuximab and erlotinib for the treatment of patients with metastatic colorectal cancer

Phase II clinical trial evaluating the combination of cetuximab and erlotinib for the treatment of patients with metastatic colorectal cancer

Posted by on Mar 19, 2013 in Colorectal cancer | 0 comments

In a nutshell This article presents the results of a phase II clinical trial that evaluated the efficacy and safety of the combination of two targeted therapies – cetuximab and erlotinib – for patients with metastatic colorectal cancer (mCRC). Some background Colorectal cancer that has spread outside the large...

Read More

Regorafenib is a new drug for the treatment of metastatic colorectal cancer after failure of previous therapies

Posted by on Mar 10, 2013 in Colorectal cancer | 0 comments

In a nutshell The present study evaluated the efficacy of a new drug, Regorafenib, for the treatment of refractory (progressing despite several lines of treatment) metastatic colorectal cancer (mCRC).  Some background Many of the patients with colorectal cancer do not present any symptoms in the early stages of the disease so the cancer...

Read More

Phase I trial to determine the safety of a new anti-cancer drug: PD 0332991

Phase I trial to determine the safety of a new anti-cancer drug: PD 0332991

Posted by on Mar 7, 2013 in Colorectal cancer | 0 comments

In a nutshell This article presents the results from the first human trial of PD 0332991, a new anti-cancer drug. The main objective of the study was to determine the safety and recommended dose for further testing. Results warrant further studies and revealed that neutropenia (low white cell count) was the main side effect. Some background Cells...

Read More

Postoperative radiotherapy prevents breast cancer recurrence and prolongs survival

Posted by on Feb 25, 2013 in Breast cancer | 0 comments

In a nutshell This study evaluated if strategies to prevent cancer recurrence are associated with prolonged survival 15 years after treatment. Their main findings were that postoperative radiation managed to prevent cancer recurrence and was associated with higher rates of long-term survival. Some background Early breast cancer is often treated...

Read More

Risks versus benefit of the ‘HIPEC’ treatment for peritoneal metastases due to colorectal cancer

Risks versus benefit of the ‘HIPEC’ treatment for peritoneal metastases due to colorectal cancer

Posted by on Feb 24, 2013 in Colorectal cancer | 0 comments

Colorectal cancer (CRC) often presents with peritoneal metastases, which have a poor outcome. This means that cancer cells have spread from the colon, appendix, or rectum to the peritoneum (a sheath that covers the abdominal organs). This article argues the pros and cons of a combined treatment for patients with peritoneal metastases from CRC. This...

Read More